Business Wire

Ferinject® approved in Chinafor the treatment of iron deficiency in adult patients

Share

Regulatory News:

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221127005020/en/

CSL Vifor and Fresenius Kabi today announced that China’s National Medical Products Administration (NMPA) has approved Ferinject®, a preparation for intravenous iron therapy for the treatment of iron deficiency in adult patients for whom oral iron preparations are ineffective, oral iron preparations cannot be used or for whom there is a clinical need to deliver iron rapidly. Ferinject® has now received marketing authorization in 85 countries worldwide.

“We are thrilled about the marketing authorization of Ferinject®, which is a milestone for Chinese patients living with iron deficiency or iron deficiency anemia”, said Hervé Gisserot, General Manager of CSL Vifor. “There is a high unmet need in China, which has the world’s largest iron deficiency population, and we are confident that Ferinject® can make a meaningful difference in the treatment of these patients. At the same time, this is another important step in our goal to globalizing and maximizing the performance of our iron franchise as we look forward to bring this treatment to market as soon as possible.”

“Marketing authorization of Ferinject® will strengthen our commitment of bringing innovative medicines for patients in China. We are guided by our corporate philosophy of caring for life and invested to putting essential medicines and technologies in the hands of people who help patients and to finding the best answers to the challenges they face”, said Yang Weiping, President of Fresenius Kabi China.

The approval of Ferinject® may also enable a more effective implementation of PBM in Chinese hospitals, where an estimated 3-4 million patients undergo elective surgery each year. In China, PBM encompasses multiple in-hospital procedures across therapeutic areas. The China National Health Commission (NHC) has announced guidelines for perioperative PBM as a health standard across China, effective as per 1 June 2022.

Marketing authorization in China is based on positive clinical results from the phase-III trial VIT-IRON-2011-004. This open label, randomized multicenter study showed that Ferinject® is an effective and well-tolerated alternative to iron sucrose for the treatment of iron deficiency anemia that can provide an improved hemoglobin response and correction of iron deficiency in Chinese patients.

CSL Vifor and Fresenius Kabi currently expect to begin to market Ferinject® in the first half of 2023, with National Reimbursement Drug List (NRDL) listing anticipated in January 2024.

About CSL Vifor

CSL Vifor is a global partner of choice for pharmaceuticals and innovative, leading therapies in iron deficiency, dialysis and nephrology & rare disease. We specialize in strategic global partnering, in-licensing and developing, manufacturing and marketing pharmaceutical products for precision healthcare, aiming to help patients around the world lead better, healthier lives. Headquartered in St. Gallen, Switzerland, CSL Vifor also includes the joint company Vifor Fresenius Medical Care Renal Pharma (with Fresenius Medical Care).

The parent company, CSL (ASX:CSL; USOTC:CSLLY), headquartered in Melbourne, Australia, employs 30,000 people and delivers its lifesaving therapies to people in more than 100 countries. For more information about CSL Vifor visit, www.cslvifor.com.

About Fresenius Kabi

Fresenius Kabi is a global healthcare company that specializes in lifesaving medicines and technologies for infusion, transfusion and clinical nutrition. The company’s products and services are used to help care for critically and chronically ill patients. Fresenius Kabi’s product portfolio comprises a comprehensive range of I.V. generic drugs, infusion therapies and clinical nutrition products as well as the devices for administering these products. In the field of biosimilars, Fresenius Kabi focuses on autoimmune diseases and oncology. In 2019, the first biosimilar product by Fresenius Kabi was launched. Within transfusion medicine and cell therapies, Fresenius Kabi offers products for collection of blood components and extracorporeal therapies.

With its corporate mission of "caring for life", the company is committed to putting essential medicines and technologies in the hands of people who help patients and finding the best answers to the challenges they face. For more information, please visit www.fresenius-kabi.com.

About Ferinject®

Ferinject®/Injectafer® (ferric carboxymaltose) is an i.v. iron therapy with market authorization in 85 countries by November 2022. More than 19 million patient years of experience have helped to establish Ferinject®/ Injectafer® as a trusted brand, with clinical benefits demonstrated by its efficacy and safety data2. Ferinject’s® quality relies on a consistent and firmly-controlled manufacturing process based on decades of experience.

About iron deficiency

Iron Deficiency affects about half of the patients with chronic kidney disease3 and chronic heart failure and is associated with reduced quality of life4, an increased risk of hospitalization5 and cardiovascular death6. Despite the serious consequences and high prevalence, of iron deficiency, the condition remains under-recognized7.

Iron plays a vital role in many bodily processes, including the production of red blood cells, effective heart and brain function, and the prevention of infection and illness. Without enough iron, the body is unable to function properly. Common symptoms include fatigue, dizziness, and shortness of breath. Iron deficiency and iron deficiency anemia is estimated to affect one in three people worldwide8, yet despite the serious consequences and high prevalence9, it remains an under-recognized condition.

Although iron deficiency can affect anyone, it is most prevalent in premenopausal women, pregnant woman and children under five10. Left untreated, it can develop into iron deficiency anemia. The effects of iron deficiency differ from person to person but can be linked to an overall decline in general health and well-being11. Even without anemia, iron deficiency can be debilitating, exacerbate an underlying chronic disease and lead to increased morbidity and mortality12. Common symptoms include fatigue11, 13, 14 pale skin13, brittle nails13, 15, craving non-food items such as dirt, clay and ice16, and an inability to concentrate11, 17. In children, iron deficiency can significantly impair cognitive and motor development18.

About Patient Blood Management (PBM)

PBM is designed to improve surgical and medical patient outcomes by optimally managing and preserving patients’ blood. Proactive identification and treatment of iron deficiency anemia in patients scheduled for elective surgery has been associated with a reduced need for blood transfusion19 , reduced length of hospital stay19, improved patient’s outcomes20, and overall healthcare expenditure reduction21.

References:

1. Ni W, Yuan X, Sun Y, et al. Anaemia and associated factors among older adults in an urban district in China: a large-scale crosssectional study. BMJ Open 2022;12:e056100. doi:10.1136/ bmjopen-2021-056100.

2. Scott Drugs. 2018 Mar;78(4):479–493. doi: 10.1007/ s40265-018-0885-7.

3. Wong MMY et al. Clin Kid J 2019:1–12; Rocha BML, et al. J Am Coll Cardiol. 2018;71(7):782–793.

4. Guedes M NDT 2021. doi: 10.1093/ndt/gfab050; Enjuanes C, et al. Int J Cardiol. 2014;174(2):268–275.

5. Guedes et al. J Am Soc Nephrol. 2021 Aug;32(8):2020-2030, Martens P, et al. Acta Cardiol. 2018;73(2):115–123.

6. Guedes et al. J Am Soc Nephrol. 2021 Aug;32(8):2020-2030; Klip IT, et al. Am Heart J. 2013;165:575–82.e3.

7. Eur J Heart Fail. 2021 Sep 3. doi: 10.1002/ejhf.2338.

8. Peyrin-Biroulet L, et al. Guidelines on the diagnosis and treatment of iron deficiency across indications: a systematic review. Am J Clin Nutr. 2015;102(6):1585-94.

9. World Health Organization. Worldwide prevalence of anaemia 1993-2005. 2008. Available at URL: http://apps.who.int/iris/bitstream/handle/10665/43894/9789241596657_eng.pdf;jsessionid=9C613E2F4D481EDEB9DE07986AFCE0C7?sequence=1. Last accessed: June 2018.

10. Hercberg S, et al. Iron deficiency in Europe. Public Health Nutr. 2007;4(2b).

11. Fernando B, et al. A guide to diagnosis of iron deficiency and iron deficiency anemia in digestive diseases. World J Gastroenterol. 2009 Oct 7; 15(37): 4638-4643.

12. Cappellini MD et al. Iron deficiency across chronic inflammatory conditions: International expert opinion on definition, diagnosis, and management. Am J Hematol. 2017 Oct;92(10):1068-1078.

13. Auerbach M, Adamson JW. How we diagnose and treat iron deficiency anemia. Am J Hematol. 2016;91(1):31-38.

14. Favrat, B., et al. (2014). Evaluation of a single dose of ferric carboxymaltose in fatigued, iron-deficient women--PREFER a randomized, placebo-controlled study. PLoS One 9(4): e94217. eCollection 2014.

15. Cashman MW, Sloan SB. Nutrition and nail disease. Clin Dermatol. 2010;28(4):420-5.

16. Barton JC, et al. Pica associated with iron deficiency or depletion: clinical and laboratory correlates in 262 non-pregnant adult outpatients. BMC Blood Disord. 2010;10:9. doi:10.1186/1471-2326-10-9.

17. Patterson A et al. Iron deficiency, general health and fatigue: Results from the Australian Longitudinal Study on Women’s Health. Qual Life Res. 2000;9:491-497.

18. World Health Organization. Nutritional anaemias: tools for effective prevention and control. 2017. Available at URL: http://www.who.int/nutrition/publications/micronutrients/anaemias-tools-prevention-control/en/. Last accessed: June 2018.

19. Froessler B. et al., Ann Surg 2016

20. Kotzé A. et al., British Journal of Anaesthesia 2012

21. Basora M. et al., Blood Transfus 2018

# # #

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

CSL Vifor Media Contact
Thomas Hutter
Mobile: +41 79 957 96 73
Email: media@viforpharma.com

CSL Investor Contact
Steve McKeon
Associate Director, Investor Relations
CSL Limited
Mobile +61 402 231 696
Email: stephen.mckeon@csl.com.au

Fresenius Kabi contacts:
China Corporate Communications
+86 010 – 59096999
cn.communications@fresenius-kabi.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

All Seas Capital Closes Maiden Fund With US$400m AUM1.2.2023 14:03:00 EET | Press release

All Seas Capital, a pan-European private capital fund that provides transformational capital solutions to leading founder- and entrepreneur-owned companies, is pleased to announce the final close of its maiden fund, All Seas Capital I SCSp (the “Fund”), with total commitments of US$400m including coinvestments. All Seas Capital’s global investor base, consisting of pension funds, sovereign wealth funds, consultants, insurance companies and banks from the US, Europe and Asia, provide a well-diversified mix of investors. Since inception to the Fund’s final close, All Seas Capital invested over US$200 million in portfolio companies, including Attivo Group (UK), Hakim Group (UK), SoMeD Santé (France) and Zimmer MedizinSysteme (Germany). All Seas Capital provides flexible long-term financing solutions to leading Western European mid-market businesses. Alongside transformational capital solutions, the All Seas team provides board level expertise to entrepreneurs and management teams who do n

ALECSO to Partner With SNC to Launch First Conference on International Organizations of Education, Science and Culture1.2.2023 13:57:00 EET | Press release

The Arab League Educational, Cultural and Scientific Organization (ALECSO), in cooperation with the Saudi National Commission for Education, Culture and Science (SNC), is set to host the inaugural edition of a major international conference on culture, science and education in the 21st century. The conference, ‘Future of Education, Science, and Culture International Organizations Forum’ (FESCIOF) will take place over two days from March 8-9, 2023, at the King Abdullah Petroleum Studies and Research Center (KAPSARC) in the Saudi capital Riyadh, with the participation of a number of major international organizations in the fields of education, culture and science. FESCIOF will host an unprecedented gathering of international organizations and global entities across a variety of sectors with the goal of enabling collaboration and facilitating cross-sectoral dialogue. Expected attendees include top international and multilateral organizations; regional institutions; national and regional p

Energy Aspects Acquires OilX, a Pioneer in AI Driven Data Analytics for Energy Markets1.2.2023 13:52:00 EET | Press release

Leading energy and macro research consultancy Energy Aspects has acquired OilX, a pioneer in AI-driven energy data analytics. The acquisition will enhance Energy Aspects’ insights as OilX’s real-time data technology complements Energy Aspects’ forward-looking analysis. OilX, in turn, will benefit from Energy Aspects’ proprietary data sets and world-class subject matter experts, improving its data-driven insights to clients. Founded in 2018 by Dr. Florian Thaler , OilX’s unique real-time energy market platform offers sophisticated ‘nowcasting’ capabilities, enabling its clients to understand energy markets as they evolve. OilX’s advanced technology utilises AI, satellite and tanker tracking data to create highly valuable proprietary data sets, and its UX design delivers high data usability. OilX’s product range covers crude oil, refined products, biofuels and NGL’s. Their platform, the world’s first real-time oil supply and demand balance, provides users with market analysis ahead of of

Major Update: B2Broker Adds Match-Trader White Label1.2.2023 13:00:00 EET | Press release

After integrating cTrader in 2022, B2Broker has continued to expand, with the integration of Match-Trader being the most recent. By adding Match-Trader, B2Broker, a worldwide provider of liquidity and technology for the FX and cryptocurrency markets, has announced the extension of its white label liquidity service. Thanks to this new integration, clients will have access to a full white label solution, highly competitive commercials, and a ready-made B2Core integration. This integration is a prime example of B2Broker's dedication to providing its clients with a complete and flexible service. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230201005066/en/ Match-Trader White Label Ecosystem (Graphic: Business Wire) Match-Trader While Label Solution To give brokers and their clients a complete Match-Trader experience, B2Broker has created a white label solution. The new service streamlines all necessary technologies into a sing

FPT Software Europe Supports DAX Company Covestro With Cloud Migration1.2.2023 11:00:00 EET | Press release

FPT Software Europe, a subsidiary of FPT Software - leading technology and IT service provider headquartered in Vietnam, has recently announced its strategic partnership with Covestro AG (Covestro). As a leading global manufacturer of polymer materials, Covestro is included in DAX stock market index among major German companies trading on the Frankfurt Stock Exchange. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230201005414/en/ FPT Tower – FPT Corporation’s head quarter in Hanoi, Vietnam (Photo: Business Wire) Entering a multi-year agreement with Covestro, FPT Software Europe is leveraging its in-depth experience, comprehensive services and best-shore model to support the DAX-listed group in the migration of 290 applications to the Amazon Web Services (AWS) cloud platform, thereby accelerating its digital transformation journey. Starting signal for the next generation of IT infrastructure Within the next few years, FPT So

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom